No observations: USFDA inspection at Cipla arm InvaGen New York plant concludes
Mumbai: Drugmaker Cipla has announced that the United States Food and Drug Administration (USFDA) has concluded inspection with zero Form 483 observations at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc., a wholly-owned subsidiary of the Company located in Hauppauge, Long Island, New York, USA.
The facility was inspected from 16th October 2023 to 25th October 2023.
"We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 16th October 2023 to 25th October 2023," the Company stated in a recent BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.